Frontiers in Oncology · 2019 · 84 citations · 29 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyChimeric Antigen Receptor T-cell TherapyCombination ImmunotherapyCytokines In Tumor ImmunityImmunotherapy For Breast CancerAdaptive Antitumor ImmunityAntitumor Cytokine ResponsesAntitumor Immune ActivationAntitumor Interferon ResponsesCd8 Positive T CellsCd8 T Cell ActivationImmunosuppressive FunctionInnate Immune Cytokines
Chimeric antigen receptor modified T cells (CAR-T) therapy is an emerging immunotherapy against malignancies. However, only limited success was obtained in solid tumors. Polyinosinic-polycytidylic acid (poly I:C), ligand of TLR3, mediates innate immune and adaptive immune and shows broad antitumor effect on many types of cancer. In the present study, we combined EGFRvIII-targeted CAR-T cells with poly I:C treatment and evaluated the synergic antitumor effect in vitro and in immunocompetent mice bearing subcutaneous colon or orthotopic breast cancer xenografts. Poly I:C significantly promoted more IL-2 and IFN γ production as well as higher lytic activity of CAR-T cells. Upon systemic administration in vivo, CAR-T cells suppressed tumor growth obviously and poly I:C significantly enhanced the suppression. Further study showed that poly I:C exerts antitumor effect partially dependent on CD8 T cells and type I IFN signaling. In addition, poly I:C decreased MDSC quantity in peripheral blood and spleen and attenuated the immunosuppressive activity of MDSC on T cell proliferation and CAR-T cytolytic function. Depletion of MDSC with anti-Gr1 Ab further increased the antitumor effect of CAR-T cells plus poly I:C treatment. In conclusion, CAR-T treatment combined with intratumoral delivery of poly I:C resulted in synergistic antitumor activity. We thus provide a rationale to translate this immunotherapeutic strategy to solid tumors.
29
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Christine E. Brown, Darya Alizadeh, Renate Starr et al. · New England Journal of Medicine · 2016 · 1.8K citations · Full text
Medicine, Immunology, Oncology +17
CD47 blockade triggers T cell–mediated destruction of immunogenic tumors
Xiaojuan Liu, Yang Pu, Kyle R. Cron et al. · Nature Medicine · 2015 · 758 citations · Full text
Life Sciences, Immunology, Oncology +14
Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers
Chengcheng Zhang, Zhe Wang, Zhi Yang et al. · Molecular Therapy · 2017 · 444 citations · Full text
Medicine, Nuclear Medicine, Oncology +17